Brokerages Set Medpace Holdings, Inc. (NASDAQ:MEDP) Price Target at $467.08

Medpace Holdings, Inc. (NASDAQ:MEDP) has been given an average recommendation of “Hold” by the fifteen ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $467.0833.

A number of research firms have recently issued reports on MEDP. Truist Financial dropped their price target on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. Mizuho set a $582.00 price target on Medpace in a research report on Wednesday, February 11th. Weiss Ratings downgraded Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. TD Cowen raised Medpace from a “sell” rating to a “hold” rating and dropped their price target for the stock from $462.00 to $419.00 in a research report on Wednesday, February 18th. Finally, Leerink Partners dropped their price target on Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 11th.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Bronstein, Gewirtz & Grossman, Faruqi & Faruqi, The Gross Law Firm, Rosen, Schall, Pomerantz, and others, issued updates this week about a pending class-action lawsuit against Medpace and reminded shareholders of upcoming lead-plaintiff deadlines, keeping legal risk in focus for the stock. Article Title
• Neutral Sentiment: The latest notices do not add new operational or financial guidance from Medpace; they mainly reiterate the same securities-fraud allegations and court deadline, so the immediate market impact is likely driven more by headline risk than by fundamentals. Article Title
• Neutral Sentiment: Short-interest data released alongside the legal headlines showed no meaningful borrowable shares reported, suggesting the move in MEDP is being driven by news flow rather than a clear short-selling signal.

Medpace Price Performance

Shares of Medpace stock opened at $447.11 on Wednesday. The stock’s fifty day moving average is $457.47 and its two-hundred day moving average is $513.36. The company has a market capitalization of $12.77 billion, a PE ratio of 28.10, a price-to-earnings-growth ratio of 2.27 and a beta of 1.18. Medpace has a 52 week low of $291.28 and a 52 week high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. During the same quarter in the prior year, the company earned $3.67 EPS. The business’s revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts anticipate that Medpace will post 17.04 earnings per share for the current year.

Insider Buying and Selling at Medpace

In related news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the sale, the president directly owned 15,000 shares in the company, valued at $6,829,500. This represents a 67.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 20.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Medpace

A number of hedge funds have recently made changes to their positions in MEDP. Optiver Holding B.V. purchased a new stake in shares of Medpace during the 3rd quarter worth $27,000. Geneos Wealth Management Inc. lifted its stake in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Medpace during the 4th quarter worth $30,000. Elyxium Wealth LLC purchased a new stake in shares of Medpace during the 4th quarter worth $30,000. Finally, Quarry LP purchased a new stake in shares of Medpace during the 3rd quarter worth $35,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.